Udai Banerji, MD @udai_banerji of The Institute of Cancer Research and Jonathan Pachter, PhD of Verastem Oncology discuss the new opportunities and RAF-MEK inhibitor CH5126766 and FAK inhibitor defactinib in an intermittent dosing schedule with expansions in KRAS mutant cancers.
Udai Banerji, MD and Jonathan Pachter, PhD on New Opportunities with RAF-MEK Inhibitor CH5126766 @udai_banerji
By Editor